The tweet was deleted by the author.
But we saved everything 🙂.
Editas Medicine has received authorization to begin its first in human clinical trial of EDIT-401, targeting patients with hyperlipidemia.
This development marks a notable milestone for the company in the field of gene editing therapies, specifically addressing hereditary cardiovascular diseases.
View post on X Loading...